Breast Cancer | China In-Depth | China | 2022

Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—including pertuzumab (Roche’s Perjeta) and ado-trastuzumab emtansine (Roche’s Kadcyla)—have launched there in the last few years. The inclusion of these therapies in the National Reimbursement Drug List (NRDL) has improved the drug-treatment rate for breast cancer in China and resulted in significant market growth. We expect many more premium-priced breast cancer therapies—currently in the late-phase pipeline—to launch in China during the forecast period, further expanding this market. However, unmet need will remain in the treatment of difficult-to-treat breast cancer populations (e.g., triple-negative disease), presenting continued commercial opportunity for developers in this space. Additionally, in view of the ongoing reforms of China’s regulatory and access and reimbursement landscape, developers—both domestic and multinational—will be increasingly encouraged to enter this market.

QUESTIONS ANSWERED

• How large is China’s drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?
• Which are the most commercially relevant drugs in China’s breast cancer therapy market, and why? What are interviewed experts’ insights into current treatments?
• What are the market access considerations for key therapies in the breast cancer pipeline in China? What sales could these agents secure in breast cancer? What are interviewed experts’ opinions of key emerging therapies?
• What are the key drivers and constraints in China’s breast cancer therapy market, and how will the market evolve over the forecast period?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

June 2022

Geography

China

Primary research

Country-specific qualitative and quantitative insights based on 5 thought-leader interviews and surveys of 75 medical oncologists.

Epidemiology

Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.

FORECAST

10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.

EMERGING THERAPIES

Phase III/preregistered: 20+ drugs; Phase II: 20+ drugs; coverage of select Phase I products.